Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?

Figure 3 All algorithms currently used to estimate risk of cardiovascular disease in the general population underestimate the actual risk of human immunodeficiency virus positive patients. Although unproven, it is likely that a combination of traditional risk factors, risk linked with some anti-retroviral agents and data on subclinical atherosclerosis collected via imaging, may improve risk prediction in the future. ASCVD: Atherosclerotic cardiovascular disease; HAART: Highly active antiretroviral therapies; HIV: Human immunodeficiency virus.